BRAF and non-small cell lung carcinoma: In this study, we retrospectively analyzed a total of 167 advanced stage NSCLC PD-L1 positive patients (≥1%) who were referred to our referral clinic for the molecular evaluation of at least five driver genes, namely, EGFR, KRAS, BRAF, ALK and ROS1.